延华智能(002178) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥162,345,419.56, representing a 25.49% increase compared to ¥129,364,923.75 in the same period last year[8] - The net profit attributable to shareholders was -¥13,928,887.42, an improvement of 27.24% from -¥19,144,506.62 year-on-year[8] - The company reported a net loss of CNY -423,380,857.63 for Q1 2021, compared to a loss of CNY -409,451,970.21 in the previous period[33] - The net profit for Q1 2021 was a loss of CNY 17,792,425.65, compared to a loss of CNY 21,453,747.50 in Q1 2020, indicating an improvement of approximately 17.5%[40] - The total operating profit for Q1 2021 was a loss of CNY 17,320,853.23, an improvement from a loss of CNY 20,907,843.89 in Q1 2020[41] Cash Flow - The net cash flow from operating activities was -¥63,576,911.93, showing a 7.38% improvement compared to -¥68,646,093.95 in the previous year[8] - The cash inflow from operating activities was CNY 252,359,593.62, compared to CNY 216,481,788.93 in the previous year, representing an increase of 16.5%[44] - The net cash flow from operating activities was -36,759,131.15 yuan, an improvement from -55,340,717.26 yuan in the previous period[48] - Cash flow from financing activities resulted in a net outflow of -13,224,191.52 yuan, a significant decrease from a net inflow of 21,465,331.95 yuan in the previous period[46] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,652,303,497.04, a decrease of 4.24% from ¥1,725,408,180.29 at the end of the previous year[8] - Current liabilities totaled CNY 888,030,550.26, down from CNY 954,156,374.15, indicating a reduction of about 6.9%[32] - The total liabilities decreased to CNY 941,149,936.70 from CNY 993,528,854.30, a reduction of about 5.3%[32] - The company's total non-current assets amounted to CNY 472,433,583.75, up from CNY 456,747,022.55, reflecting an increase of approximately 3.6%[31] Inventory and Prepayments - The company's inventory increased by 48.34% compared to the beginning of the period, primarily due to increased contract performance costs by subsidiaries[15] - The company reported a 67.31% increase in prepayments compared to the beginning of the period, attributed to project procurement payments to promote project progress[15] Research and Development - Research and development expenses increased by 35.07% compared to the previous period, mainly due to increased investment in medical software development by subsidiaries[16] - Research and development expenses for Q1 2021 were CNY 13,614,490.15, up from CNY 10,079,893.42 in the previous year, marking a 35.5% increase[41] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 57,672, with the largest shareholder holding 17.41% of the shares[11] - The company’s basic earnings per share for Q1 2021 was -0.02, compared to -0.03 in the same period last year[40] Government Support and Other Income - The company received government subsidies amounting to ¥912,880.97 during the reporting period[9] - The company reported an investment income of CNY 1,280,838.17, compared to CNY 1,106,654.17 in the same quarter last year, showing a growth of 15.7%[41]